Site icon OncologyTube

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021.

For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss Amivantamab and Mobocertinib for EGFR Exon 20.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Exit mobile version